NCT06517732

Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation

Prospective, Observational, Multicenter Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation (ANIMA-R)

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 107 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

ANIMA-R is an observational, prospective, non-interventional, multicenter study to assess real-world effectiveness of secukinumab in the treatment of Hidradenitis Suppurativa (HS).

Detailed description

The index date will be the date of secukinumab initiation. During the study, data will be collected from patients receiving routine secukinumab treatment, which is representative of the actual patient population. The attending physician will decide whether to prescribe secukinumab based on the approved instructions for medical use in a routine clinical setting, regardless of the patient's participation in a non-interventional study.

Conditions

• Hidradenitis Suppurativa

Interventions

Type	Name	Description
OTHER	Secukinumab	This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.

Timeline

• Start date: 2024-07-26
• Primary completion: 2026-12-31
• Completion: 2026-12-31
• First posted: 2024-07-24
• Last updated: 2026-04-16

Locations

19 sites across 1 country: Russia